"The fact that it was a simple blood test, it was absolutely objective, and it was…non-invasive…made it very attractive," says William J. Catalona, MD.
As part of the Urology Times' 50th Anniversary Innovation Celebration, William J. Catalona, MD, discusses how prostate-specific antigen (PSA) testing has greatly impacted the field of urology over the past 50 years. Catalona is a professor of urology at Northwestern University in Chicago, Illinois.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.